Sequenta is a venture funded biotech company dedicated to the discovery and development of clinical diagnostics based on a revolutionary new platform for understanding immune system status. A profound revolution in the cost of DNA sequencing has enabled the company to develop brand new approaches to measuring the most variable part of the human genome: the immune cell receptor genes. The incredible diversity created by these genes are at the heart of a large number of conditions critical to human health and disease allowing the company to be in a position to inform a large number of clinical decisions using a single powerful assay.
The company was founded in 2008 by entrepreneurs who previously founded ParaAllele BioScience, a successful startup company sold to Affymetrix in 2005.
Sequenta was acquired by Adaptive Biotechnologies in 2015